These updated Phase 1a data strengthen the clinical case for TTX-MC138, with durable disease control and supportive biomarker evidence. Watch for Phase 2a data in ctDNA-positive colorectal cancer and any dose-expansion strategy announcements as the next catalysts.
Price Chart
Executive Summary
TransCode Therapeutics reported updated Phase 1a clinical data for TTX-MC138, showing a 71.4% stable disease rate in 14 efficacy-evaluable patients with advanced solid tumors, with 3 patients remaining progression-free at 12 months. The primary safety endpoint was met with no dose-limiting toxicities, and exploratory biomarker data showed treatment-associated antitumor immune activation.
Key Facts
- 71.4% stable disease rate (10 of 14 efficacy-evaluable patients) as best overall response
- 57.1% disease control rate at Cycle 3 Day 1; 35.7% at Cycle 6 Day 1
- 3 of 14 efficacy-evaluable patients remain progression-free at 12 months
- No dose-limiting toxicities reported; primary safety endpoint met
- 98 total doses administered; highest dose level 4.8 mg/kg well tolerated
- 40% of evaluable patients (6 of 15) achieved GMI >1.3 in post-hoc analysis
- Exploratory RNA-sequencing showed treatment-associated antitumor immune activation
Financial Impact
No financial figures reported; clinical-stage company with no product revenue
Risk Factors
- Small sample size (14 efficacy-evaluable patients) limits statistical reliability
- Company is pre-revenue and requires additional funding to continue operations
- Phase 2a data in colorectal cancer may not replicate these Phase 1a findings
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-111170 |
| Document: tm2626237d1_ex99-1.htm | 0001104659-26-111170 |
| Document: 0001104659-26-111170-index-headers.html | 0001104659-26-111170 |
| Document: 0001104659-26-111170-index.html | 0001104659-26-111170 |
| Document: 0001104659-26-111170.txt | 0001104659-26-111170 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | 8-K | $1.71 $1.71 | ▼ −0.26% | ▼ −0.23% | $1.67 (−2.34%) |
Sep 21, 2026 5w ago | 3 | $1.77 $1.68 | ▼ −5.08% | ▼ −4.52% | $1.67 (−5.65%) |
Sep 11, 2026 6w ago | 8-K | $1.65 $1.63 | ▲ +1.21% | ▲ +3.48% | $1.67 (−1.21%) |
Jul 2, 2026 16w ago | 8-K | $8.61 $4.22 | ▼ −50.99% | ▼ −51.84% | $1.67 (−80.60%) |
Jun 18, 2026 18w ago | 8-K | $4.70 $8.27 | ▲ +75.96% | ▲ +75.42% | $1.67 (−64.47%) |
Jun 3, 2026 20w ago | 8-K | $5.04 $8.61 | ▲ +70.83% | ▲ +71.83% | $1.67 (−66.87%) |
May 26, 2026 22w ago | DEFA14A | $5.39 $4.94 | ▲ +8.35% | ▲ +6.40% | $1.67 (+69.02%) |
Apr 30, 2026 25w ago | S-3 | $7.83 $5.44 | ▲ +30.59% | ▲ +35.85% | $1.67 (+78.67%) |
Apr 7, 2026 29w ago | 8-K | $8.70 $7.74 | ▲ +11.03% | ▲ +20.82% | $1.67 (+80.80%) |
Mar 3, 2026 34w ago | DEFA14A | $9.84 $8.69 | ▼ −11.69% | ▼ −7.27% | $1.67 (−83.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers